Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 284

1.

The effectiveness of screening for prostate cancer: a nested case-control study.

Concato J, Wells CK, Horwitz RI, Penson D, Fincke G, Berlowitz DR, Froehlich G, Blake D, Vickers MA, Gehr GA, Raheb NH, Sullivan G, Peduzzi P.

Arch Intern Med. 2006 Jan 9;166(1):38-43.

PMID:
16401808
2.
3.

Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality: a case-control study.

Weinmann S, Richert-Boe KE, Van Den Eeden SK, Enger SM, Rybicki BA, Shapiro JA, Weiss NS.

Epidemiology. 2005 May;16(3):367-76. Erratum in: Epidemiology. 2005 Jul;16(4):515.

PMID:
15824554
4.

Case-control prostate cancer screening studies should not exclude subjects with lower urinary tract symptoms.

Godley PA, Carpenter WR.

J Clin Epidemiol. 2007 Feb;60(2):176-80. Epub 2006 Sep 28.

PMID:
17208124
6.

Factors influencing use of the prostate-specific antigen screening test in primary care.

Moran WP, Cohen SJ, Preisser JS, Wofford JL, Shelton BJ, McClatchey MW.

Am J Manag Care. 2000 Mar;6(3):315-24.

7.

Screening digital rectal examination and prostate cancer mortality: a population-based case-control study.

Jacobsen SJ, Bergstralh EJ, Katusic SK, Guess HA, Darby CH, Silverstein MD, Oesterling JE, Lieber MM.

Urology. 1998 Aug;52(2):173-9. Review.

PMID:
9697778
8.

Racial differences in screening for prostate cancer in the elderly.

Gilligan T, Wang PS, Levin R, Kantoff PW, Avorn J.

Arch Intern Med. 2004 Sep 27;164(17):1858-64.

PMID:
15451760
9.

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.

Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr.

J Clin Oncol. 2007 Jul 20;25(21):3076-81.

PMID:
17634486
10.

A nested case-control study of the effectiveness of screening for prostate cancer: research design.

Concato J, Peduzzi P, Kamina A, Horwitz RI.

J Clin Epidemiol. 2001 Jun;54(6):558-64.

PMID:
11377115
11.

Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program.

Cohen L, Fouladi RT, Babaian RJ, Bhadkamkar VA, Parker PA, Taylor CC, Smith MA, Gritz ER, Basen-Engquist K.

Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):610-7.

12.

Comparative study on the prevalence of clinically detectable prostate cancer in patients with and without bladder cancer.

Kurokawa K, Ito K, Yamamoto T, Takechi H, Miyamoto S, Suzuki K, Yamanaka H.

Urology. 2004 Feb;63(2):268-72.

PMID:
14972469
13.

Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study.

Kopec JA, Goel V, Bunting PS, Neuman J, Sayre EC, Warde P, Levers P, Fleshner N.

J Urol. 2005 Aug;174(2):495-9; discussion 499.

PMID:
16006879
14.

Characteristics of prostate cancer detected by digital rectal examination only.

Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ.

Urology. 2007 Dec;70(6):1117-20.

PMID:
18158030
15.

Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.

Price MM, Hamilton RJ, Robertson CN, Butts MC, Freedland SJ.

Urology. 2008 May;71(5):787-91. doi: 10.1016/j.urology.2007.11.036. Epub 2008 Feb 11.

PMID:
18267334
16.

The impact of informed consent on patient interest in prostate-specific antigen screening.

Wolf AM, Nasser JF, Wolf AM, Schorling JB.

Arch Intern Med. 1996 Jun 24;156(12):1333-6.

PMID:
8651843
17.

Prostate cancer screening and mortality: a case-control study (United States).

Weinmann S, Richert-Boe K, Glass AG, Weiss NS.

Cancer Causes Control. 2004 Mar;15(2):133-8.

PMID:
15017125
18.

Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.

Lim LS, Sherin K; ACPM Prevention Practice Committee..

Am J Prev Med. 2008 Feb;34(2):164-70. doi: 10.1016/j.amepre.2007.10.003. Review. Erratum in: Am J Prev Med. 2008 May;34(5):454.

PMID:
18201648
19.

Screening for prostate cancer: updated experience from the Tyrol study.

Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schönitzer D, Severi G, Robertson C, Boyle P, Bartsch G.

Can J Urol. 2005 Feb;12 Suppl 1:7-13; discussion 92-3.

PMID:
15780158
20.

Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).

Srinualnad S, Charoenkraikamol C, Toraksa S, Uiprasertkul M, Amornvesukit T, Taweemonkongsap T, Udompunturak S, Nualyong C, Tantiwong A.

J Med Assoc Thai. 2006 Jan;89(1):37-42.

PMID:
16583579

Supplemental Content

Support Center